Your browser doesn't support javascript.
loading
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.
Branche, Angela R; Rouphael, Nadine G; Losada, Cecilia; Baden, Lindsey R; Anderson, Evan J; Luetkemeyer, Anne F; Diemert, David J; Winokur, Patricia L; Presti, Rachel M; Kottkamp, Angelica C; Falsey, Ann R; Frey, Sharon E; Rupp, Richard; Bäcker, Martín; Novak, Richard M; Walter, Emmanuel B; Jackson, Lisa A; Little, Susan J; Immergluck, Lilly C; Mahgoub, Siham M; Whitaker, Jennifer A; Babu, Tara M; Goepfert, Paul A; Fusco, Dahlene N; Atmar, Robert L; Posavad, Christine M; Netzl, Antonia; Smith, Derek J; Telu, Kalyani; Mu, Jinjian; Makowski, Mat; Makhene, Mamodikoe K; Sonja, Crandon; Montefiori, David C; Roberts, Paul C; Beigel, John H.
Afiliação
  • Branche AR; University of Rochester VTEU, Rochester, NY.
  • Rouphael NG; Emory University Hope Clinic, Decatur, GA.
  • Losada C; Emory University Hope Clinic, Decatur, GA.
  • Baden LR; Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Anderson EJ; Center for Childhood Infections and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA.
  • Luetkemeyer AF; Zuckerberg San Francisco General, University of California San Francisco, San Francisco, CA.
  • Diemert DJ; George Washington Vaccine Research Unit, George Washington University, Washington D.C.
  • Winokur PL; University of Iowa College of Medicine, Iowa City, IA.
  • Presti RM; Washington University School of Medicine, St. Louis, MO.
  • Kottkamp AC; NYU VTEU Manhattan Research Clinic at NYU Grossman School of Medicine, New York, NY.
  • Falsey AR; University of Rochester VTEU, Rochester, NY.
  • Frey SE; Saint Louis University, Center for Vaccine Development, St. Louis, MO.
  • Rupp R; University of Texas Medical Branch, Galveston, TX.
  • Bäcker M; NYU VTEU Long Island Research Clinic at NYU Long Island School of Medicine, Mineola, NY.
  • Novak RM; University of Illinois at Chicago-Project WISH, Chicago, IL.
  • Walter EB; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC.
  • Jackson LA; Kaiser Permanente Washington Health Research Institute, Seattle, WA.
  • Little SJ; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA.
  • Immergluck LC; Morehouse School of Medicine, Atlanta, GA.
  • Mahgoub SM; Howard University College of Medicine, Howard University Hospital, Washington D.C.
  • Whitaker JA; Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX.
  • Babu TM; Departments of Medicine, Epidemiology, and Laboratory Medicine & Pathology, University of Washington, Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Goepfert PA; University of Alabama at Birmingham, Birmingham, AL.
  • Fusco DN; Tulane University School of Medicine, New Orleans, LA.
  • Atmar RL; Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX.
  • Posavad CM; IDCRC Laboratory Operations Unit - Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.
  • Netzl A; Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UK.
  • Smith DJ; Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UK.
  • Telu K; The Emmes Company, LLC, Rockville, MD.
  • Mu J; The Emmes Company, LLC, Rockville, MD.
  • Makowski M; The Emmes Company, LLC, Rockville, MD.
  • Makhene MK; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Sonja C; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Montefiori DC; Duke University, Durham, NC.
  • Roberts PC; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Beigel JH; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
medRxiv ; 2023 Mar 31.
Article em En | MEDLINE | ID: mdl-37034641
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2023 Tipo de documento: Article